Evidence following guidelines: Another COVID-19 paradox.
作者信息
Heymann Warren R
机构信息
Cooper Medical School of Rowan University, Marlton, New Jersey.
出版信息
J Am Acad Dermatol. 2021 Jan;84(1):37-38. doi: 10.1016/j.jaad.2020.10.070. Epub 2020 Oct 29.
Abstract
摘要
相似文献
1
Evidence following guidelines: Another COVID-19 paradox.
J Am Acad Dermatol. 2021 Jan;84(1):37-38. doi: 10.1016/j.jaad.2020.10.070. Epub 2020 Oct 29.
2
COVID, Biologics, and Psoriasis Therapy.
J Am Acad Dermatol. 2020 Dec;83(6):1577-1578. doi: 10.1016/j.jaad.2020.09.005. Epub 2020 Sep 10.
3
Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?
Int J Dermatol. 2020 Sep;59(9):1144-1145. doi: 10.1111/ijd.15059. Epub 2020 Jul 25.
4
Biological therapies, asthma and coronavirus disease 2019.
Curr Opin Allergy Clin Immunol. 2021 Dec 1;21(6):597-601. doi: 10.1097/ACI.0000000000000783.
5
Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.
Int J Dermatol. 2020 Sep;59(9):1043-1056. doi: 10.1111/ijd.15028. Epub 2020 Jul 3.
6
Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations.
J Am Acad Dermatol. 2021 Nov;85(5):1113-1116. doi: 10.1016/j.jaad.2021.08.031. Epub 2021 Aug 23.
7
Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic.
J Am Acad Dermatol. 2020 Jul;83(1):288-292. doi: 10.1016/j.jaad.2020.04.143. Epub 2020 May 4.
8
Continuation and Discontinuation Rates of Biologics in Dermatology Patients During COVID-19 Pandemic.
J Cutan Med Surg. 2021 Nov-Dec;25(6):646-647. doi: 10.1177/12034754211024125. Epub 2021 Jun 9.
9
COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy.
J Am Acad Dermatol. 2020 Jul;83(1):292-294. doi: 10.1016/j.jaad.2020.04.165. Epub 2020 May 6.
10
Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review.
Dermatol Ther. 2020 Nov;33(6):e13867. doi: 10.1111/dth.13867. Epub 2020 Jul 7.
引用本文的文献
1
COVID-19 infection risk in patients on immunosuppressive/immunomodulator therapy: A single center study.
Dermatol Ther. 2021 Nov;34(6):e15126. doi: 10.1111/dth.15126. Epub 2021 Sep 19.
本文引用的文献
1
Covid-19 pandemic and the skin.
Int J Dermatol. 2020 Nov;59(11):1312-1319. doi: 10.1111/ijd.15189. Epub 2020 Sep 21.
2
Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study.
J Am Acad Dermatol. 2021 Jan;84(1):70-75. doi: 10.1016/j.jaad.2020.09.009. Epub 2020 Sep 11.
3
Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries.
J Dermatolog Treat. 2022 May;33(3):1208-1212. doi: 10.1080/09546634.2020.1808154. Epub 2020 Oct 30.
4
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
5
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.
Br J Dermatol. 2020 Aug;183(2):373-374. doi: 10.1111/bjd.19158. Epub 2020 May 28.
Zotero 插件